HCM
AXSM icon

Hollencrest Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Hollencrest Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Sell
100
-100
-50% -$21.7K ﹤0.01% 698
2026
Q1 		$33.8K Buy
200
+160
+400% +$27.6K ﹤0.01% 631
2025
Q4 		$7.31K Buy
+40
New +$5.58K ﹤0.01% 858
2025
Q2 		– Sell
-87
Closed -$10.1K – 1134
2025
Q1 		$10.1K Buy
+87
New +$9.91K ﹤0.01% 771

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hollencrest Capital Management's AXSM Position: Q2 2026 in Review

Hollencrest Capital Management reduced its Axsome Therapeutics (AXSM) stake by 50% in Q2 2026, selling an estimated $21.7K and leaving 100 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Hollencrest Capital Management first reported a position in AXSM in Q1 2025 and has held it in 4 quarters since. The position peaked at $33.8K in Q1 2026. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Hollencrest Capital Management held 100 shares of Axsome Therapeutics worth $24.5K as of Q2 2026.
  • Hollencrest Capital Management sold 100 Axsome Therapeutics shares in Q2 2026, an estimated $21.7K.
  • Axsome Therapeutics made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #698 holding.
  • Hollencrest Capital Management first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Hollencrest Capital Management's Axsome Therapeutics position peaked at $33.8K in Q1 2026.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.